Effectiveness of fremanezumab to treat episodic, chronic, or difficult-to-treat migraine

Summaries 3 min 299

Font Size

Created On: 04/07/2022

This retrospective, panel-based online chart review aimed to evaluate the effectiveness of fremanezumab across various subsets of adult patients with difficult-to-treat migraine, chronic migraine, or episodic migraine in a real-world clinical setup.

See All

Key take away

Use of fremanezumab is effective to treat migraine regardless of type of migraine or the presence of factors that contribute to difficult-to-treat migraine.

Background

Method

Patients who were diagnosed with chronic migraine or episodic migraine; age ≥ eighteen years during first fremanezumab commencement; ≥ 2 estimations of monthly migraine days; ≥ 1 follow-up visit since first commencement; and ≥ 1 dose of fremanezumab were included. During the follow-up period, alterations in monthly headache days (MHD) and monthly migraine days (MMD) were evaluated.

Prior exposure to a different calcitonin gene-related peptide pathway-targeted monoclonal antibody (CGRP mAb), generalized anxiety disorder, major depressive disorder, and diagnosis of medication overuse were assessed in subsets of patients by type of migraine (chronic migraine/episodic migraine) and in subsets with difficult-to-treat migraine. From 421 clinicians and 1003 participants, the collection of data was done.

Result

At month 6, the mean (percent) decrease from baseline in MMD in episodic migraine people, chronic migraine people, generalized anxiety disorder subgroup, medication overuse subgroup, major depressive disorder subgroup, and the previous CGRP mAb exposure subgroup is depicted in Table 1:

Improvements in generalized anxiety disorder or major depressive disorder severity were reported by 45.8% and 45.5% of people with comorbid generalized anxiety disorder or major depressive disorder.

Conclusion

Sustained decrease in MMD and MHD supported fremanezumab's efficacy in people suffering from EM or CM and people having DTT migraine, including people with acute medication overuse, comorbid major depressive disorder, comorbid generalized anxiety disorder, and previous exposure to another CGRP pathway–targeted mAb.